Kymera Therapeutics, Inc. [KYMR] Filings

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

10-Q 1 kymr-20240630.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number: 001-39460

KYMERA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware	81-2992166
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

500 North Beacon Street, 4th Floor Watertown, Massachusetts	02472
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (857) 285-5300

Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

    KYMR

    The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 2, 2024, the registrant had 61,753,243 shares of common stock, $0.0001 par value per share, outstanding.

Summary of the Material and Other Risks Associated with Our Business

•

We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.

•

We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.

•

We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.

•

We are still early in our development efforts, with disclosed programs in pre-clinical, Phase 1 and Phase 2 development. If we are unable to advance them through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

•

We cannot be certain of the timely completion or outcome of our preclinical testing, including our STAT6 and TYK2 programs. In addition, the results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of later-stage clinical trials.

•

Our approach to the discovery and development of product candidates based on our PegasusTM platform is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.

•

Business interruptions resulting from any pandemic or similar public health crises could cause a disruption to our supply chain or the development of our product candidates and adversely impact our business.

•

We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

•

If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

•

Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

•

Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

•

We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.

•

If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, express or implied statements about:

•

the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and future clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

•

our ability to continue to construct PegasusTM, our drug discovery platform, and to enable a rational and effective drug discovery and development engine;

•

the timing and the success of preclinical development efforts for our STAT6 and TYK2 programs and clinical studies under our IRAK4, STAT3 and MDM2 programs;

•

our plans to submit investigational new drug applications to the U.S. Food and Drug Administration, or FDA for current and future product candidates;

•

the subsequent initiation of planned clinical trials;

•

our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;

•

our potential ability to manufacture our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;

•

the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;

•

our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;

•

our ability to obtain and maintain regulatory approval of our product candidates;

•

our ability to commercialize our products, if approved;

•

the pricing and reimbursement of our product candidates, if approved;

•

the implementation of our business model, and strategic plans for our business, product candidates, and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•

estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;

•

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

•

future agreements with third parties in connection with the commercialization of product candidates and any other approved product;

•

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

•

our financial performance;

•

the rate and degree of market acceptance of our product candidates;

•

regulatory developments in the United States and foreign countries;

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

•

the success of competing therapies that are or may become available;

•

our ability to attract and retain key scientific or management personnel;

•

the impact of laws and regulations;

•

developments relating to our competitors and our industry;

•

the effect of any pandemics, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

iii

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss	2
	Condensed Consolidated Statements of Stockholders’ Equity	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31
PART II.	OTHER INFORMATION	32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	80
Item 3.	Defaults Upon Senior Securities	80
Item 4.	Mine Safety Disclosures	80
Item 5.	Other Information	80
Item 6.	Exhibits	81
Signatures		82

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share amounts)

(Unaudited)


	June 30, 2024			December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	67,612		$	109,966
Marketable securities (Note 4)		442,341			264,915
Accounts receivable		—			15,000
Contract assets		1,704			3,762
Prepaid expenses and other current assets		13,750			11,674
Total current assets	$	525,407		$	405,317
Marketable securities, non-current (Note 4)		192,445			61,434
Property and equipment, net (Note 6)		51,735			48,134
Right-of-use assets, operating leases		48,704			52,945
Other non-current assets		1,889			2,118
Restricted cash		5,841			5,811
Total assets	$	826,021		$	575,759
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	6,510		$	7,075
Accrued expenses (Note 8)		23,780			33,864
Deferred revenue		19,259			37,883
Operating lease liabilities		11,424			5,068
Finance lease liabilities		992			1,277
Other current liabilities		178			524
Total current liabilities	$	62,143		$	85,691
Non-current liabilities
Deferred revenue, net of current portion		3,189			16,768
Operating lease liabilities, net of current portion		74,822			77,028
Finance lease liabilities, net of current portion		943			1,301
Total liabilities	$	141,097		$	180,788
Stockholders’ equity:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2024 and December 31, 2023, 61,572,383 and 55,390,259 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		6			6
Additional paid-in capital		1,308,388			926,269
Accumulated deficit		(621,371	)		(530,752	)
Accumulated other comprehensive loss		(2,099	)		(552	)
Total stockholders’ equity		684,924			394,971
Total liabilities and stockholders’ equity	$	826,021		$	575,759

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three and six months ended June 30, 2024 and 2023

(In thousands, except for share and per share amounts)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Collaboration Revenue	$	25,650		$	16,513		$	35,937		$	25,979
Operating expenses:
Research and development	$	59,202		$	45,767		$	108,021		$	87,994
General and administrative		17,373			14,129			31,747			26,694
Impairment of long-lived assets		—			—			4,925			—
Total operating expenses		76,575			59,896			144,693			114,688
Loss from operations		(50,925	)		(43,383	)		(108,756	)		(88,709	)
Other income (expense):
Interest and other income		8,924			4,632			18,268			9,085
Interest and other expense		(61	)		(48	)		(131	)		(103	)
Total other income:		8,863			4,584			18,137			8,982
Net loss	$	(42,062	)	$	(38,799	)	$	(90,619	)	$	(79,727	)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities		(322	)		(597	)		(1,547	)		1,314
Total comprehensive loss	$	(42,384	)	$	(39,396	)	$	(92,166	)	$	(78,413	)

Net loss	$	(42,062	)	$	(38,799	)	$	(90,619	)	$	(79,727	)
Net loss per share, basic and diluted	$	(0.58	)	$	(0.67	)	$	(1.26	)	$	(1.37	)
Weighted average common stock outstanding, basic and diluted		73,059,398			58,326,963			71,908,963			58,257,387

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the three months ended June 30, 2024 and 2023

(In thousands, except for share amounts)

(Unaudited)


	Common Stock				Additional Paid in		Accumulated			Accumulated Other Comprehensive			Total Stockholders’
	Shares		Value		Capital		Deficit			Gain/(Loss)			Equity
Balance at March 31, 2023		55,276,226	$	6	$	889,755	$	(424,718	)	$	(3,038	)	$	462,005
Exercise of stock options		67,987		—		676		—			—			676
Vesting restricted stock		6,623		—		—		—			—			—
Issuance of shares under employee stock purchase plan		39,423		—		962		—			—			962
Stock-based compensation expense		—		—		11,181		—			—			11,181
Unrealized loss on marketable securities		—		—		—		—			(597	)		(597	)
Net loss		—		—		—		(38,799	)		—			(38,799	)
Balance at June 30, 2023		55,390,259	$	6	$	902,574	$	(463,517	)	$	(3,635	)	$	435,428

Balance at March 31, 2024		61,353,146	$	6	$	1,292,283	$	(579,309	)	$	(1,777	)	$	711,203
Exercise of stock options		74,318		—		630		—			—			630
Vesting restricted stock		80,694		—		—		—			—			—
Issuance of shares under employee stock purchase plan		64,225		—		1,134		—			—			1,134
Stock-based compensation expense		—		—		14,341		—			—			14,341
Unrealized loss on marketable securities		—		—		—		—			(322	)		(322	)
Net loss		—		—		—		(42,062	)		—			(42,062	)
Balance at June 30, 2024		61,572,383	$	6	$	1,308,388	$	(621,371	)	$	(2,099	)	$	684,924

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the six months ended June 30, 2024 and 2023

(In thousands, except for share amounts)

(Unaudited)


	Common Stock				Additional Paid in			Accumulated				Accumulated Other Comprehensive			Total Stockholders'
	Shares		Value		Capital			Deficit				Gain/(Loss)			Equity
Balance at December 31, 2022		55,039,380	$	6	$	878,884		$	(383,790	)		$	(4,949	)	$	490,151
Exercise of stock options		276,692		—		2,163			—				—			2,163
Vesting restricted stock		34,764		—		—			—				—			—
Issuance of shares under employee stock purchase plan		39,423		—		962			—				—			962
Stock-based compensation expense		—		—		20,565			—				—			20,565
Unrealized gain on marketable securities		—		—		—			—				1,314			1,314
Net loss		—		—		—			(79,727	)			—			(79,727	)
Balance at June 30, 2023		55,390,259	$	6	$	902,574		$	(463,517	)		$	(3,635	)	$	435,428

Balance at December 31, 2023		55,585,305	$	6	$	926,269		$	(530,752	)		$	(552	)	$	394,971
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs of $14.9 million		3,884,158	$	—		301,373	—		—		—		—			301,373
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million		1,519,453		—		48,740	—		—		—		—			48,740
Exercise of stock options		355,339		—		4,562			—				—			4,562
Vesting restricted stock		163,903		—		—			—				—			—
Issuance of shares under employee stock purchase plan		64,225		—		1,135			—				—			1,135
Stock-based compensation expense		—		—		26,309			—				—			26,309
Unrealized loss on marketable securities		—		—		—			—				(1,547	)		(1,547	)
Net loss		—		—		—			(90,619	)			—			(90,619	)
Balance at June 30, 2024		61,572,383	$	6	$	1,308,388		$	(621,371	)		$	(2,099	)	$	684,924

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the six months ended June 30, 2024 and 2023

(In thousands)

(Unaudited)


	Six Months Ended June 30,
	2024			2023
Operating activities
Net loss	$	(90,619	)	$	(79,727	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		26,309			20,565
Lease impairment charge		4,925			—
Depreciation and amortization		3,399			1,779
Premiums and discounts on available-for-sale marketable securities		(7,093	)		(2,743	)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(2,076	)		(3,994	)
Accounts receivable		15,000			—
Contract asset		2,059			(1,585	)
Other long term assets		227			—
Accounts payable		106			(513	)
Accrued expenses and other current liabilities		(7,591	)		(6,252	)
Deferred revenue		(32,203	)		(18,537	)
Operating lease right-of-use assets		1,244			2,055
Operating lease liabilities		4,149			9,554
Other assets and liabilities		(363	)		174
Net cash used in operating activities	$	(82,527	)	$	(79,224	)
Investing activities
Purchase of property and equipment, net		(12,091	)		(14,777	)
Purchases of investments		(526,860	)		(114,477	)
Maturities of investments		223,986			189,677
Net cash (used in) provided by investing activities	$	(314,965	)	$	60,423
Financing activities
Proceeds from issuance of common stock and accompanying pre-funded warrants from public offering, net of underwriting discounts and issuance costs		301,373			—
Proceeds from issuance of common stock through At-The Market Sales Agreement, net of issuance costs		48,740			—
Proceeds from stock option exercises		4,562			2,163
Proceeds from employee stock purchase plan		1,135			962
Payments on finance leases		(642	)		(661	)
Net cash provided by financing activities	$	355,168		$	2,464
Net decrease in cash, cash equivalents and restricted cash		(42,324	)		(16,337	)
Cash, cash equivalents and restricted cash at beginning of period		115,777			74,524
Cash, cash equivalents and restricted cash at end of period	$	73,453		$	58,187
Supplemental disclosure of cash flow activities
Right-of-use assets obtained in exchange for new operating lease liabilities	$	—		$	48,833
Cash paid for interest		90			78
Supplemental disclosure of noncash investing and financing activities
Property and equipment purchases included in accounts payable and accrued expenses	$	853		$	1,061

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of each of the periods shown above:


	June 30,
	2024		2023
Cash and cash equivalents	$	67,612	$	52,386
Restricted cash		5,841		5,801
Total cash, cash equivalents, and restricted cash	$	73,453	$	58,187

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Nature of Business

Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the “Company”. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company’s ability to access capital and uncertainty of market acceptance of products.

The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit of $621.4 million as of June 30, 2024. The Company has funded these losses principally through issuance of preferred stock, convertible notes, common stock, including its initial public offering and concurrent private placement completed in August 2020 (“IPO”), follow-on offering and concurrent private placement completed in July 2021 (“2021 Follow-on”) offering, August 2022 Private Investment in Public Equity (“PIPE”) offering, follow-on offering completed in January 2024 ("2024 Follow-on"), sales under our Sales Agreement with Cowen, and from cash proceeds received in connection with the Company’s collaboration agreements with Vertex Pharmaceuticals Incorporated (“Vertex”) and Genzyme Corporation (“Sanofi”) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure.

As of June 30, 2024, the Company had cash, cash equivalents and marketable securities of $702.4 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these condensed consolidated financial statements.

The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials.

Private Investment in Public Equity “PIPE” offering

On August 18, 2022, the Company and certain accredited investors entered into a securities purchase agreement pursuant to which the Company agreed to sell and issue to such investors in a private placement (i) an aggregate of 2,769,228 shares of the Company’s common stock at a purchase price of $26.00 per share, and (ii) 3,000,000 pre-funded warrants to purchase common stock, at a purchase price of $25.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share of common stock. The offering closed on August 22, 2022, resulting in net proceeds of $149.8 million after offering expenses.

2024 Follow-on Public Offering

On January 9, 2024, the Company completed a follow-on offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The Company issued and sold 3,884,158 shares of common stock, including full exercise of the underwriters’ over-allotment option to purchase an additional 1,633,663 shares, at a public offering price of $25.25 per share. Additionally, in lieu of common stock to certain investors, the Company issued and sold pre-funded warrants to purchase 8,640,594 shares of its common stock at a public offering price of $25.2499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company were approximately $316.2 million.

Pre-funded warrants

In connection with certain offerings mentioned above the Company has issued pre-funded warrants to purchase common stock in lieu of common stock. As the pre-funded warrants are indexed to the Company’s common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company’s consolidated balance sheets. The pre-funded warrants are exercisable at any time. The holders of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company.

During the three and six months ended June 30, 2024, no pre-funded warrants were exercised. As of June 30, 2024, there were 11,640,594 pre-funded warrants outstanding.

2. Summary of Significant Accounting Policies

The accompanying condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying condensed consolidated financial statements and notes.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation

The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the SEC on February 22, 2024.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments necessary, all of which were normal and recurring, for the fair statement of the Company’s financial position as of June 30, 2024, and the results of operations, equity, and cash flows for the six months ended June 30, 2024 and 2023. The results for the three and six months ended June 30, 2024 are not necessarily indicative of the results for the year ended December 31, 2024 or for any future period.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements in the 2023 Annual Report on Form 10-K.

3. Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of June 30, 2024 and December 31, 2023 (in thousands):


	Fair Value Measurements at June 30, 2024:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents
Money market fund	$	36,428	$	—	$	—	$	36,428
US treasuries		13,450		—		—		13,450
US government agencies		—		2,995		—		2,995
Commercial Paper		—		10,960		—		10,960
Marketable securities, current
US treasuries		164,958		—		—		164,958
US government agencies		—		90,727		—		90,727
Commercial Paper		—		23,588		—		23,588
Corporate bonds		—		163,068		—		163,068
Marketable securities, non-current
US treasuries		28,600		—		—		28,600
US government agencies		—		30,470		—		30,470
Corporate bonds		—		133,375		—		133,375
Restricted cash		5,841		—		—		5,841
Total	$	249,277	$	455,183	$	—	$	704,460


	Fair Value Measurements at December 31, 2023:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents
Money market fund	$	78,010	$	—	$	—	$	78,010
US treasuries		27,985		—		—		27,985
Commercial Paper		997		—		—		997
Marketable securities, current
US treasuries		23,253		—		—		23,253
US government agencies		—		114,384		—		114,384
Corporate bonds		—		127,278		—		127,278
Marketable securities, non-current
US treasuries		—		—		—		-
US government agencies		—		28,307		—		28,307
Corporate bonds		—

Kymera Therapeutics, Inc. [KYMR] Filings
10-Q	[2024-08-07]
10-Q	[2024-05-02]
10-K	[2024-02-22]
10-Q	[2023-11-02]
10-Q	[2023-08-03]
10-Q	[2023-05-04]
10-K	[2023-02-23]
10-Q	[2022-11-03]
10-Q	[2022-08-09]
10-Q	[2022-05-03]
10-K	[2022-02-24]
10-Q	[2021-11-10]
10-Q	[2021-08-06]
S-1	[2021-06-28]
10-Q	[2021-05-06]
10-K	[2021-03-11]
10-Q	[2020-11-05]
S-1	[2020-07-31]